A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer
- 1.5k Downloads
Ovarian cancer, which ranks fifth in cancer deaths among women, is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) is the most common histologic type, with the 5-year survival for all stages estimated at 45.6%. This rate increases to more than 70% in the minority of patients who are diagnosed at an early stage, but declines to 35% in the vast majority of patients diagnosed at advanced stage. Recurrent EOC is incurable. Platinum sensitivity (or lack thereof) is a major determinant of prognosis. The current standard treatment is primary surgery followed by platinum-based chemotherapy. In recurrent platinum-resistant/platinum-refractory EOC, sequential single-agent salvage chemotherapy is superior to multiagent chemotherapy. Multiagent regimens increase toxicity without clear benefit; however, no preferred sequence of single agents is recommended. The impact of targeted therapies and immunotherapies on progression-free survival and overall survival, which remains dismal, is under active investigation. Currently, clinical trials offer the best hope for the development of a new treatment paradigm in this recalcitrant disease.
KeywordsEpithelial ovarian cancer Platinum resistant Platinum refractory Epigenetic VEGF inhibitor
The authors wish to thank and acknowledge Dr. Harry Lybeck, possibly the world’s longest living academic professor and physician, currently 98 years old (and counting), for his contributions to this manuscript. Having earned his M.D. and Ph.D. while serving in WWII, Dr. Lybeck climbed to the top of the academic hill but is far from over it. With 70 years of medical experience, Dr. Lybeck is the epitome of a caring, compassionate physician who prioritizes others over himself.
Compliance with ethical standards
Conflict of interest
This article does not contain any studies with human participants or animals performed by any of the authors.
- 3.National Institutes of Health. National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer Stat Facts: Ovarian cancer https://seer.cancer.gov/statfacts/html/ovary.html. Accessed 19 Jan 2017.
- 5.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed 19 Jan 2017.
- 6.Look KY. Epidemiology, etiology, and screening of ovarian cancer. In: Rubin SC, Sutton GP, editors. Ovarian cancer. Philadelphia: Lippincott, Williams and Wilkins; 2001. p. 168–74.Google Scholar
- 8.Winter WE III, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26(1):83.CrossRefPubMedGoogle Scholar
- 14.Bamias A, Bamia C, Zagouri F, Kostouras E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents. Oncology. 2013;84(3):158–65.CrossRefPubMedGoogle Scholar
- 15.Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A, AGO and GINECO study group. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–12.CrossRefPubMedGoogle Scholar
- 16.National Institutes of Health. National Cancer Institute. Surveillance, epidemiology, and end results program. Statistical summaries: cancer stat fact sheets (ovary) and cancer statistics review (CSR), 1975–2013. http://www.seer.cancer.gov/statistics/summaries.html. Accessed 19 Jan 2017.
- 17.Ushijima K. Treatment for recurrent ovarian cancer—at first relapse. J Oncol. 2010;2010:7 (Article ID 497429).Google Scholar
- 18.Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O’Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M. Ovarian Cancer, Version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(9):1134–63.CrossRefGoogle Scholar
- 25.Gordon AN, Tonda M, Sun S, Rackoff W. Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8.CrossRefPubMedGoogle Scholar
- 31.Ganghadaran SGD. Management of platinum resistant—refractory ovarian cancer: a short review. J Cancer Res Treat. 2016;4(2):32–6.Google Scholar
- 36.Kothari R, Argenta P, Fowler J, Carter J, Shimp W. Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature. Arch oncol Inst Oncol Sremska Kamenica Yugosl. 2010;18(1–2):32–5.Google Scholar
- 39.McClung EC, Wenham RM. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. Int J Women’s Health. 2016;8:59–75.Google Scholar
- 43.Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Degesys A, Kim MM, Oronsky AL, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C. RRx-001 in refractory small-cell lung carcinoma: a case report of a partial response after a third reintroduction of platinum doublets. Case Rep Oncol. 2016;9(1):171–6.CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Hamanishi J, Mandai M, Ikeda T, et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2014; 32, abstract 5511, ASCO Annual Meeting.Google Scholar
- 50.Varga A, Piha-Paul SA, Ott PA, et al. Antitumor activity and safety of pembrolizumab in patients with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. J Clin Oncol. 2015;33(15 Suppl.):5510.Google Scholar
- 51.Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.CrossRefPubMedPubMedCentralGoogle Scholar
- 53.FDA News Release. FDA grants accelerated approval to new treatment for advanced ovarian cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm. Accessed 19 Jan 2017.